000109092 001__ 109092
000109092 005__ 20230519145514.0
000109092 0247_ $$2doi$$a10.3390/antiox10111853
000109092 0248_ $$2sideral$$a125454
000109092 037__ $$aART-2021-125454
000109092 041__ $$aeng
000109092 100__ $$0(orcid)0000-0003-2656-6750$$aFuentes-Broto, Lorena$$uUniversidad de Zaragoza
000109092 245__ $$aEffects of daily melatonin supplementation on visual loss, circadian rhythms, and hepatic oxidative damage in a rodent model of retinitis pigmentosa
000109092 260__ $$c2021
000109092 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109092 5203_ $$aRetinitis pigmentosa (RP) is a group of inherited neurodegenerative diseases characterized by a progressive loss of visual function that primarily affect photoreceptors, resulting in the complete disorganization and remodeling of the retina. Progression of the disease is enhanced by increased oxidative stress in the retina, aqueous humor, plasma, and liver of RP animal models and patients. Melatonin has beneficial effects against age-related macular degeneration, glaucoma, and diabetic retinopathy, in which oxidative stress plays a key role. In the present study, we used the P23HxLE rat as an animal model of RP. Melatonin treatment (10 mgkg b.w. daily in drinking water for 6 months) improved the parameters of visual function and decreased the rate of desynchronization of the circadian rhythm, both in P23HxLE and wild-type rats. Melatonin reduced oxidative stress and increased antioxidant defenses in P23HxLE animals. In wild-type animals, melatonin did not modify any of the oxidative stress markers analyzed and reduced the levels of total antioxidant defenses. Treatment with melatonin improved visual function, circadian synchronization, and hepatic oxidative stress in P23HxLE rats, an RP model, and had beneficial effects against age-related visual damage in wild-type rats.
000109092 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B08-17R$$9info:eu-repo/grantAgreement/ES/ISCIII/PI13-01124
000109092 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000109092 590__ $$a7.675$$b2021
000109092 592__ $$a1.008$$b2021
000109092 594__ $$a6.5$$b2021
000109092 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b50 / 297 = 0.168$$c2021$$dQ1$$eT1
000109092 593__ $$aBiochemistry$$c2021$$dQ1
000109092 591__ $$aFOOD SCIENCE & TECHNOLOGY$$b12 / 144 = 0.083$$c2021$$dQ1$$eT1
000109092 593__ $$aPhysiology$$c2021$$dQ1
000109092 591__ $$aCHEMISTRY, MEDICINAL$$b4 / 63 = 0.063$$c2021$$dQ1$$eT1
000109092 593__ $$aMolecular Biology$$c2021$$dQ1
000109092 593__ $$aClinical Biochemistry$$c2021$$dQ1
000109092 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000109092 700__ $$aPerdices, Lorena
000109092 700__ $$0(orcid)0000-0002-9250-9060$$aSegura, Francisco$$uUniversidad de Zaragoza
000109092 700__ $$0(orcid)0000-0003-2710-1875$$aOrduna-Hospital, Elvira$$uUniversidad de Zaragoza
000109092 700__ $$aInsa-Sánchez, Gema$$uUniversidad de Zaragoza
000109092 700__ $$aSánchez-Cano, Ana I.
000109092 700__ $$aCuenca, Nicolás
000109092 700__ $$aPinilla, Isabel
000109092 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000109092 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000109092 7102_ $$12002$$2647$$aUniversidad de Zaragoza$$bDpto. Física Aplicada$$cÁrea Óptica
000109092 773__ $$g10, 11 (2021), 1853 [16 pp]$$pAntioxidants$$tAntioxidants$$x2076-3921
000109092 8564_ $$s1790542$$uhttps://zaguan.unizar.es/record/109092/files/texto_completo.pdf$$yVersión publicada
000109092 8564_ $$s2708211$$uhttps://zaguan.unizar.es/record/109092/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000109092 909CO $$ooai:zaguan.unizar.es:109092$$particulos$$pdriver
000109092 951__ $$a2023-05-18-15:14:55
000109092 980__ $$aARTICLE